What is the current recommended approach to managing hypertension in 2026?

Hypertension Management in 2026

Blood Pressure Diagnostic Thresholds and Classification

The 2024 European Society of Cardiology (ESC) guidelines define hypertension as office blood pressure ≥140/90 mmHg, while the 2017 ACC/AHA guidelines use a lower threshold of ≥130/80 mmHg. 1, 2 For clinical practice in 2026, the ESC threshold of ≥140/90 mmHg represents the international consensus and should guide your diagnostic approach, though you must recognize that patients with BP 130-139/80-89 mmHg and high cardiovascular risk require intervention. 1

ESC Blood Pressure Categories (2024):

• Optimal: <120/70 mmHg 1
• Normal: 120-129/70-84 mmHg 1
• Elevated (High-Normal): 130-139/85-89 mmHg 1
• Grade 1 Hypertension: 140-159/90-99 mmHg 1
• Grade 2 Hypertension: 160-179/100-109 mmHg 1
• Grade 3 Hypertension: ≥180/110 mmHg 1

Diagnostic Confirmation Requirements:

• Confirm hypertension with out-of-office blood pressure monitoring (home or 24-hour ambulatory) before starting medication to exclude white-coat hypertension 1, 2, 3
• Home BP threshold: ≥135/85 mmHg confirms hypertension 1
• 24-hour ambulatory BP threshold: ≥130/80 mmHg confirms hypertension 1
• Diagnosis requires an average of ≥2 readings on ≥2 separate occasions 2, 4

Blood Pressure Treatment Targets

For most adults under 65 years with hypertension, target a systolic blood pressure of 120-129 mmHg and diastolic 70-79 mmHg if treatment is well tolerated. 1 This represents the most recent and highest-quality evidence from the 2024 ESC guidelines, which analyzed cardiovascular outcomes across multiple trials and found continuing benefit at progressively lower systolic pressures. 1

Specific Target Ranges by Population:

• Adults <65 years: 120-129/70-79 mmHg (optimal target within this range is 120 mmHg systolic) 1, 2
• Adults ≥65 years (ambulatory, non-institutionalized): <130 mmHg systolic 1, 2
• Adults ≥85 years: Continue treatment lifelong if tolerated; consider <140/90 mmHg if frailty or symptomatic orthostatic hypotension present 1
• Diabetes mellitus: <130/80 mmHg 1, 2, 4
• Chronic kidney disease: <130/80 mmHg 1, 2
• Established cardiovascular disease: 120-129/70-79 mmHg 1, 5

Critical Diastolic Consideration:

In high-risk patients, do not lower diastolic pressure below 70 mmHg, as excessive reduction may increase adverse cardiovascular events. 1, 2 The optimal diastolic range is 70-79 mmHg. 1, 2

When to Initiate Pharmacologic Therapy

For Confirmed Hypertension (≥140/90 mmHg):

Start lifestyle measures AND pharmacologic treatment simultaneously—do not delay medication beyond 3 months. 1, 5 Prompt initiation reduces cardiovascular risk regardless of baseline CVD risk. 1

For Elevated Blood Pressure (130-139/80-89 mmHg):

Begin with intensive lifestyle modifications for 3 months. 1, 2 Add pharmacologic therapy if BP remains ≥130/80 mmHg AND the patient has any of the following high-risk conditions:

• 10-year ASCVD risk ≥10% (using SCORE2 for ages 40-69 or SCORE2-OP for ages ≥70) 1, 2
• Established cardiovascular disease 1, 2, 5
• Diabetes mellitus 1, 2
• Chronic kidney disease (stage 3+ or albuminuria ≥300 mg/day) 1, 2
• Hypertension-mediated organ damage (left ventricular hypertrophy, retinopathy, microalbuminuria) 1, 2
• Familial hypercholesterolemia 1, 2

First-Line Pharmacologic Therapy

The four endorsed first-line drug classes are thiazide/thiazide-like diuretics, ACE inhibitors, angiotensin receptor blockers (ARBs), and long-acting dihydropyridine calcium channel blockers (CCBs). 1, 2, 4 All four classes produce comparable office BP reductions of approximately 9/5 mmHg when used as monotherapy. 1, 2

Initial Treatment Strategy by Blood Pressure Level:

Stage 1 Hypertension (140-159/90-99 mmHg):

• Start with single-agent monotherapy and titrate upward before adding a second drug 1, 2, 4
• Reassess monthly until target achieved 1, 2

Stage 2 Hypertension (≥160/100 mmHg or >20/10 mmHg above goal):

Begin with a two-drug combination from different first-line classes, preferably as a single-pill formulation. 1, 2 Single-pill combinations markedly improve medication adherence and persistence compared to separate pills. 1, 2

Preferred Two-Drug Combinations:

1. ACE inhibitor or ARB + thiazide/thiazide-like diuretic 1, 2
2. ACE inhibitor or ARB + dihydropyridine calcium channel blocker 1, 2

Optimal First-Line Agent for General Population:

Chlorthalidone 12.5-25 mg once daily is the optimal first-line drug for uncomplicated hypertension because it provides 24-hour BP control and superior cardiovascular outcomes demonstrated in the ALLHAT trial (>50,000 participants). 2, 4 In ALLHAT, chlorthalidone reduced heart failure incidence by 38% compared to amlodipine and stroke incidence by 15% compared to lisinopril. 2

Population-Specific First-Line Drug Selection

Black Patients Without Heart Failure or CKD:

Start with a thiazide diuretic (chlorthalidone preferred) or calcium channel blocker. 1, 2, 4 ACE inhibitors and ARBs are 30-36% less effective for stroke prevention in this population due to lower renin activity. 1, 2 ARBs may be better tolerated than ACE inhibitors (less cough, angioedema) but confer no additional cardiovascular benefit. 2

Diabetes Mellitus:

Prefer an ACE inhibitor or ARB as initial therapy to protect renal function, especially when albuminuria ≥300 mg/day is present. 1, 2, 4 Target BP <130/80 mmHg. 1, 2

Chronic Kidney Disease (Stage 3+ or Albuminuria):

ACE inhibitor or ARB is first-line to decelerate eGFR decline and reduce proteinuria. 1, 2 Target BP <130/80 mmHg. 1, 2

Post-Myocardial Infarction or Stable Ischemic Heart Disease:

Combine a β-blocker with an ACE inhibitor or ARB as foundational therapy. 2, 5 If angina persists and BP remains uncontrolled, add a dihydropyridine CCB. 2 Target BP <130/80 mmHg. 2, 5

Heart Failure with Reduced Ejection Fraction:

Use a three-drug regimen: ACE inhibitor or ARB + β-blocker + diuretic. 1, 2

Established Cardiovascular Disease:

Start pharmacological treatment promptly with ACE inhibitor or ARB + dihydropyridine CCB, preferably as a single-pill combination. 5 Do not delay with lifestyle modifications alone—initiate both simultaneously. 5 Target systolic BP 120-129 mmHg if tolerated. 5

Young Adults (<40 Years):

Perform comprehensive screening for secondary hypertension causes (renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing syndrome, coarctation). 1 In obese young adults, begin with obstructive sleep apnea evaluation. 1

Pregnancy:

Switch to methyldopa, extended-release nifedipine, or labetalol. 1, 2 ACE inhibitors, ARBs, and direct renin inhibitors are absolutely contraindicated due to fetal toxicity. 1, 2 Target BP <140/90 mmHg but avoid diastolic <80 mmHg. 1

Treatment Escalation Algorithm

If BP Remains Uncontrolled on Two-Drug Combination:

Escalate to triple therapy: ACE inhibitor or ARB + dihydropyridine CCB + thiazide/thiazide-like diuretic, preferably as a single-pill combination. 1, 5

Resistant Hypertension (BP ≥130/80 mmHg on ≥3 drugs including a diuretic):

1. Confirm true resistance with out-of-office monitoring and assess adherence 2
2. Identify contributing factors: obesity, excess alcohol, high sodium intake, NSAIDs, obstructive sleep apnea 2
3. Screen for secondary causes, especially primary aldosteronism (measure renin and aldosterone in all adults with confirmed hypertension) 1, 2
4. Optimize diuretic therapy; use loop diuretics in CKD 2
5. Add a mineralocorticoid receptor antagonist (e.g., spironolactone) 1, 2
6. Refer to hypertension specialist if uncontrolled after 6 months 1, 2

Essential Lifestyle Modifications

All individuals with BP ≥120/70 mmHg should adopt comprehensive lifestyle measures before or alongside drug therapy. 1

• Sodium restriction: approximately 2 g/day (equivalent to 5 g salt/day) 1, 4
• Potassium intake: 0.5-1.0 g/day increase through potassium-enriched salt (75% sodium chloride, 25% potassium chloride) or fruits/vegetables 1 (monitor serum potassium if CKD or taking potassium-sparing medications) 1
• Aerobic exercise: ≥150 min/week moderate-intensity or 75 min/week vigorous exercise, complemented with resistance training 2-3 times/week 1
• Weight management: target BMI 20-25 kg/m² and waist circumference <94 cm (men) or <80 cm (women) 1
• Dietary pattern: Mediterranean or DASH diet 1, 4
• Alcohol restriction: <100 g/week of pure alcohol; preferably avoid completely 1
• Sugar restriction: limit free sugar to maximum 10% of energy intake; discourage sugar-sweetened beverages 1
• Smoking cessation: mandatory and independently reduces cardiovascular events 1

Monitoring and Follow-Up

• After initiating or adjusting therapy: review patients monthly until BP target achieved 1, 2, 5
• Once controlled: follow-up every 3-5 months for maintenance 1, 2
• Dose adjustments: space at least 4 weeks apart to allow full BP response 2
• Baseline laboratory evaluation: serum creatinine, eGFR, potassium, fasting glucose, lipid panel, urine albumin-to-creatinine ratio 1, 2
• When prescribing ACE inhibitors, ARBs, or diuretics: repeat creatinine, eGFR, and potassium within 1-2 weeks of initiation, after each dose increase, and annually thereafter 2
• Acceptable creatinine increase: up to 50% above baseline or to 3 mg/dL (whichever is greater) 2
• Out-of-office BP monitoring: essential to assess treatment response, detect white-coat effect, and identify masked uncontrolled hypertension 2, 3

Critical Agents to Avoid

β-Blockers as First-Line:

Do not use β-blockers as first-line therapy in uncomplicated hypertension, especially in patients >60 years. 1, 2 They are approximately 36% less effective than CCBs and 30% less effective than thiazides for stroke prevention. 1, 2 Reserve for compelling indications: angina, post-MI, heart failure with reduced ejection fraction, atrial fibrillation. 1

Dual RAS Blockade:

Never combine an ACE inhibitor with an ARB (or add a direct renin inhibitor). 1, 2, 5 This increases risk of hyperkalemia and acute kidney injury without added cardiovascular benefit. 1, 2

α-Blockers:

Not recommended as first-line because they are less effective for cardiovascular disease prevention than thiazide diuretics. 2 In ALLHAT, doxazosin was associated with an 80% higher rate of heart failure compared to chlorthalidone. 2

Renal Denervation:

Not recommended as first-line therapy because adequately powered outcome trials demonstrating safety and cardiovascular benefit are lacking. 1

Common Pitfalls to Avoid

• Delaying combination therapy in Stage 2 hypertension (≥140/90 mmHg) increases cardiovascular risk 2, 5
• Using β-blockers as first-line in patients >60 years without compelling indication leads to inferior stroke prevention 1, 2
• Excessive diastolic lowering below 60 mmHg in high-risk patients may increase adverse cardiovascular events 1, 2
• Failing to employ out-of-office BP monitoring can miss white-coat or masked hypertension, compromising management 2, 3
• Relying on a single office measurement for diagnosis; improper technique can falsely raise readings by 10-30 mmHg 2
• Using hydrochlorothiazide doses <25 mg daily as monotherapy; such low doses are unproven or less effective in outcome trials 2
• Continuing ACE inhibitors or ARBs during pregnancy is contraindicated due to fetal toxicity 1, 2
• Withdrawing treatment in older adults due to asymptomatic orthostatic hypotension; maintain lifelong treatment if tolerated 1